Amphastar Pharma (AMPH)

Nevertheless, the discouraging prospect of more pain ahead doesn't mean you need to sit in cash. Your better option is to stay invested, but go on the defensive. You can achieve this, by focusing on names like these seven safe stocks. Each one is likely to see their resiliency continue in this down market.

7 Safe Small-Cap Stocks to Buy Now

By Louis Navellier and the InvestorPlace Research Staff May 12, 2022

If you're looking for resilient plays with high upside potential, consider these seven safe small-cap stocks to buy.

7 “A”-Rated Stocks to Ground Your Portfolio

By Louis Navellier and the InvestorPlace Research Staff Mar 17, 2022

It's a good time to make sure you have "A"-rated stocks in your portfolio. Many of the ones here have my triple-"A" rating.

7 Safe Stocks to Rely On When the Market Swerves

By Louis Navellier and the InvestorPlace Research Staff Feb 9, 2022

When markets that have flown so high for so long start to tumble, along with an economy that transitioning, safe stocks are essential.

7 Stocks to Buy for June

By James Brumley, InvestorPlace Feature Writer May 28, 2019

TerraForm Power, Zillow Group and Boston Scientific are just some of the top stocks to buy as May turns into June.

3 Stocks to Watch on Tuesday: Amphastar Pharmaceuticals Inc (AMPH), Coupa Software Inc (COUP) and Kronos Worldwide, Inc. (KRO)

By Karl Utermohlen, InvestorPlace Writer Mar 13, 2018

Amphastar Pharmaceuticals (AMPH), Coupa Software (COUP) and Kronos Worldwide (KRO) reported on their quarterly earnings after the bell Monday.

Why Seattle Genetics, Inc. (SGEN), Endologix, Inc. (ELGX) and Amphastar Pharmaceuticals Inc (AMPH) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer Dec 27, 2016

Owners of healthcare stocks Endologix (ELGX), Amphastar Pharmaceuticals (AMPH) and Seattle Genetics (SGEN) each had a run of bad luck on Tuesday.

Amphastar Pharma (AMPH)

AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024

7 Biotech Stocks to Buy on the Dip: June 2024

Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Amphastar Pharma (AMPH)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

AMPH Stock Predictions, Articles, and Amphastar Pharma News

Subscriber Sign in